Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive… read more.
A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an… read more.
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has… read more.
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the proportion of adolescents living with overweight or… read more.
A new guideline to help health care providers manage obesity in children and adolescents takes a patient-centred approach, emphasizing behavioural and psychological supports that focus on outcomes valued… read more.
EMA’s human medicines committee (CHMP) has finalised its review of Mysimba (naltrexone / bupropion), a medicine used for weight management in adults with obesity or overweight. The review… read more.
Allurion Technologies, Inc. announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with… read more.
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading… read more.
Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor… read more.
Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy… read more.
Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
